CL2009000089A1 - Processes for preparing a derivative of y-amino-o-biphenyl-x-methyl-pentanoic acid, intermediate compounds and their preparation process; use of the compounds in the synthesis of nep inhibitor compounds, useful in cardiovascular diseases, such as hypertension, congestive heart failure, among others. - Google Patents
Processes for preparing a derivative of y-amino-o-biphenyl-x-methyl-pentanoic acid, intermediate compounds and their preparation process; use of the compounds in the synthesis of nep inhibitor compounds, useful in cardiovascular diseases, such as hypertension, congestive heart failure, among others.Info
- Publication number
- CL2009000089A1 CL2009000089A1 CL2009000089A CL2009000089A CL2009000089A1 CL 2009000089 A1 CL2009000089 A1 CL 2009000089A1 CL 2009000089 A CL2009000089 A CL 2009000089A CL 2009000089 A CL2009000089 A CL 2009000089A CL 2009000089 A1 CL2009000089 A1 CL 2009000089A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- synthesis
- biphenyl
- amino
- methyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/22—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from lactams, cyclic ketones or cyclic oximes, e.g. by reactions involving Beckmann rearrangement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
LA INVENCIÓN SE REFIERE A UN PROCESO PARA PRODUCIR INHIBIDORES DE NEP O PRO-FÁRMACOS<br /> DE LOS MISMOS, EN PARTICULAR INHIBIDORES DE NEP QUE COMPRENDEN UNA ESTRUCTURA BASE DE<br /> ÁCIDO Y-AMINO-Ó-BIFENIL-A-METIL-ALCANOICO, O DE UN ÉSTER DE ÁCIDO. CON DETALLE, LOS<br /> PROCESOS, DE ACUERDO CON LA PRESENTE INVENCION, SE RELACIONAN POR ÚLTIMO CON LA<br /> SÍNTESIS DE INTERMEDIARIOS PARA PREPARAR LOS INHIBIDORES DE NEP ANTERIORES, ES DECIR,<br /> LOS COMPUESTOS DE ACUERDO CON LA FÓRMULA (1), O UNA SAL DE LOS MISMOS QUE SE OBTIENE<br /> A PARTIR DE LA REDUCCIÓN DE UN COMPUESTO INTERMEDIARIO DE FÓRMULA (2) COMO SE MUESTRA<br /> A CONTINUACIÓN:<br /> EN DONDE R1 Y R2 SON, INDEPENDIENTEMENTE UNO DEL OTRO, HIDROGENO O UN GRUPO PROTECTOR DE NITROGENO,<br /> Y R3 ES UN GRUPO CARBOXILO O UN GRUPO ESTER, DE PREFERENCIA UN GRUPO CARBOXILO O ALQUIL-ESTER.<br /> COMPLEMENTARIAMENTE LA INVENCION SE REFIERE A LOS COMPUESTOS INTERMEDIARIOS DE DICHOS<br /> INHIBIDORES DE NEP ASI COMO A LA SINTESIS DE DICHOS COMPUESTOS INTERMEDIARIOS.<br /> THE INVENTION REFERS TO A PROCESS FOR PRODUCING NEP INHIBITORS OR PRO-DRUGS <br /> OF THE SAME, IN PARTICULAR NEP INHIBITORS THAT INCLUDE A BASE STRUCTURE OF <br /> ACID AND-AMINO-OR-BIPHENYL-A- METHYL-ALKANOIC, OR OF AN ACID ESTER. IN DETAIL, THE <br /> PROCESSES, IN ACCORDANCE WITH THE PRESENT INVENTION, LASTLY RELATE TO THE SYNTHESIS OF INTERMEDIARIES TO PREPARE THE ABOVE NEP INHIBITORS, THAT IS, <br /> THE COMPOUNDS IN ACCORDANCE WITH THE FORMULA (1), OR A SALT OF THE SAME THAT IS OBTAINED <br /> FROM THE REDUCTION OF AN INTERMEDIARY COMPOUND OF FORMULA (2) AS SHOWN <br /> BELOW: <br /> WHERE R1 AND R2 ARE, INDEPENDENTLY ONE OF THE OTHER, HYDROGEN OR A NITROGEN PROTECTIVE GROUP, <br /> AND R3 IS A CARBOXYL GROUP OR AN ESTER GROUP, PREFERABLY A CARBOXYL OR ALKYL-ESTER GROUP. <br /> COMPLEMENTARY TO THE INVENTION. REFERS TO THE INTERMEDIARY COMPOUNDS OF SUCH INTERMEDIARY <br /> NEP INHIBITORS AS WELL AS THE SYNTHESIS OF SUCH INTERMEDIARY COMPOUNDS. <br />
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08150353 | 2008-01-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2009000089A1 true CL2009000089A1 (en) | 2010-01-22 |
Family
ID=40758693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2009000089A CL2009000089A1 (en) | 2008-01-17 | 2009-01-16 | Processes for preparing a derivative of y-amino-o-biphenyl-x-methyl-pentanoic acid, intermediate compounds and their preparation process; use of the compounds in the synthesis of nep inhibitor compounds, useful in cardiovascular diseases, such as hypertension, congestive heart failure, among others. |
Country Status (29)
Country | Link |
---|---|
US (4) | US8580974B2 (en) |
EP (1) | EP2245009B1 (en) |
JP (2) | JP5739667B2 (en) |
KR (1) | KR101587668B1 (en) |
CN (2) | CN101952249B (en) |
AR (1) | AR070176A1 (en) |
AU (1) | AU2009204759B2 (en) |
BR (1) | BRPI0906764A2 (en) |
CA (1) | CA2711529C (en) |
CL (1) | CL2009000089A1 (en) |
CO (1) | CO6290677A2 (en) |
EC (1) | ECSP10010405A (en) |
ES (1) | ES2602564T3 (en) |
GT (1) | GT201000211A (en) |
HU (1) | HUE030606T2 (en) |
IL (1) | IL206664A0 (en) |
MA (1) | MA31951B1 (en) |
MX (1) | MX2010007842A (en) |
MY (1) | MY169425A (en) |
NZ (2) | NZ600119A (en) |
PE (1) | PE20091364A1 (en) |
PL (1) | PL2245009T3 (en) |
PT (1) | PT2245009T (en) |
RU (2) | RU2513521C2 (en) |
SG (1) | SG187491A1 (en) |
SI (1) | SI2245009T1 (en) |
TN (1) | TN2010000304A1 (en) |
TW (1) | TWI422370B (en) |
WO (1) | WO2009090251A2 (en) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR070176A1 (en) * | 2008-01-17 | 2010-03-17 | Novartis Ag | SYNTHESIS PROCESSES OF NEP INHIBITORS, INTERMEDIATE COMPOUNDS AND USE OF THE SAME IN SYNTHESIS |
US8450496B2 (en) * | 2009-03-24 | 2013-05-28 | Hoffman-La Roche Inc. | Process for the preparation of propionic acid derivatives |
AR076706A1 (en) | 2009-05-28 | 2011-06-29 | Novartis Ag | AMINOBUTIRIC DERIVATIVES REPLACED AS NEPRILISINE INHIBITORS |
MX2011012628A (en) | 2009-05-28 | 2011-12-14 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors. |
RU2534619C2 (en) | 2009-09-23 | 2014-11-27 | Чжэцзян Цзючжоу Фармасьютикл Ко., Лтд. | Method of obtaining n-acylbiphenylalanine |
JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors |
MX2012008483A (en) * | 2010-01-22 | 2012-08-15 | Novartis Ag | Intermediates of neutral endopeptidase inhibitors and preparation method thereof. |
AU2011295170B2 (en) | 2010-08-23 | 2014-12-18 | Novartis Ag | Process for the preparation of intermediates for the manufacture of NEP inhibitors |
ES2608780T3 (en) | 2010-08-23 | 2017-04-17 | Novartis Ag | New process for the preparation of intermediaries useful for the preparation of NEP inhibitors |
CN103080077B (en) * | 2010-08-23 | 2015-06-10 | 诺华股份有限公司 | Process for the preparation of intermediates for the manufacture of NEP inhibitors |
US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
NZ611528A (en) | 2010-12-15 | 2015-06-26 | Theravance Biopharma R & D Ip Llc | Neprilysin inhibitors |
DK2651896T3 (en) | 2010-12-15 | 2015-10-05 | Theravance Biopharma R & D Ip Llc | Neprilysininhibitorer |
KR101854874B1 (en) | 2011-02-17 | 2018-05-04 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | Substituted aminobutyric derivatives as neprilysin inhibitors |
WO2012154249A1 (en) | 2011-02-17 | 2012-11-15 | Theravance, Inc. | Substituted aminobutyric derivatives as neprilysin inhibitors |
JP5959075B2 (en) | 2011-05-31 | 2016-08-02 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | Neprilysin inhibitor |
CA2835216A1 (en) | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
ES2642883T3 (en) | 2011-05-31 | 2017-11-20 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
TWI560172B (en) | 2011-11-02 | 2016-12-01 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
WO2013181332A1 (en) | 2012-05-31 | 2013-12-05 | Theravance, Inc. | Nitric oxide donor neprilysin inhibitors |
ES2710932T3 (en) | 2012-06-08 | 2019-04-29 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
SI2864292T1 (en) | 2012-06-08 | 2017-07-31 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
NZ704741A (en) | 2012-08-08 | 2017-10-27 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors |
KR20150119107A (en) | 2013-02-14 | 2015-10-23 | 노파르티스 아게 | Substituted bisphenyl butanoic acid derivatives as nep inhibitors with improved in vivo efficacy |
KR20150119109A (en) | 2013-02-14 | 2015-10-23 | 노파르티스 아게 | Substituted bisphenyl butanoic phosphonic acid derivatives as nep (neutral endopeptidase) inhibitors |
ES2634218T3 (en) | 2013-03-05 | 2017-09-27 | Theravance Biopharma R&D Ip, Llc | Neprilysin inhibitors |
CN110590606B (en) * | 2013-11-15 | 2023-02-17 | 豪夫迈·罗氏有限公司 | Process for preparing pyrimidylcyclopentane compounds |
MX2016009759A (en) | 2014-01-30 | 2016-11-17 | Theravance Biopharma R&D Ip Llc | 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors. |
MX2016009760A (en) | 2014-01-30 | 2016-11-08 | Theravance Biopharma R&D Ip Llc | Neprilysin inhibitors. |
DK3218351T3 (en) | 2014-11-14 | 2019-09-16 | Zentiva Ks | PROCEDURE FOR MANUFACTURING, INSULATING AND CLEANING PHARMACEUTICAL APPLICABLE FORMS OF AHU-377 |
ES2883557T3 (en) * | 2014-12-19 | 2021-12-09 | Basf Se | Composition for use in a process for the preparation of optically active carbonyl compounds |
JP6766055B2 (en) | 2015-02-11 | 2020-10-07 | セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー | (2S, 4R) -5- (5'-chloro-2'-fluorobiphenyl-4-yl) -4- (ethoxyoxalylamino) -2-hydroxymethyl-2-methylpentanoic acid as a neprilysin inhibitor |
TW201632493A (en) | 2015-02-13 | 2016-09-16 | 諾華公司 | New process |
ES2857101T3 (en) | 2015-02-19 | 2021-09-28 | Theravance Biopharma R&D Ip Llc | (2R,4R)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid |
CN106146351B (en) * | 2015-04-03 | 2020-09-11 | 博瑞生物医药(苏州)股份有限公司 | Method for producing biaryl substituted 4-amino-butyric acids or derivatives thereof |
CN105061263B (en) * | 2015-08-11 | 2017-03-15 | 苏州楚凯药业有限公司 | A kind of preparation method of nep inhibitor intermediate |
CN105152980B (en) * | 2015-09-11 | 2017-03-29 | 浙江永宁药业股份有限公司 | N tertbutyloxycarbonyls(4S)‑(To phenylphenylmethyl)4 amino(2R)The chiral method for preparing of methylbutanoic acid |
WO2017051326A1 (en) | 2015-09-23 | 2017-03-30 | Novartis Ag | New processes and intermediates useful in synthesis of nep inhibitors |
RU2769445C2 (en) | 2015-12-10 | 2022-03-31 | Новартис Аг | New method and new intermediate compounds |
BR112018011788A2 (en) | 2015-12-11 | 2018-12-04 | Zentiva Ks | (2r, 4s) -5- (biphenyl-4-yl) -4 - [(3-carboxypropionyl) amino] -2-methylpentanoic acid ethyl ester solid forms, their salts and a preparation method |
PT3408260T (en) | 2016-03-08 | 2021-07-23 | Theravance Biopharma R&D Ip Llc | Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof |
JP6944473B2 (en) | 2016-07-05 | 2021-10-06 | ノバルティス アーゲー | A new method for early sacubitril intermediates |
EP3500549B1 (en) | 2016-08-17 | 2020-12-16 | Novartis AG | New processes and intermediates for nep inhibitor synthesis |
CN110088079A (en) | 2016-12-23 | 2019-08-02 | 诺华股份有限公司 | New method for early stage husky card cloth song intermediate |
EP3421455B1 (en) * | 2017-06-29 | 2019-03-27 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of chiral 3-amino-piperidins, useful intermediates for the preparation of tofacitinib |
CN109912508B (en) * | 2019-04-30 | 2022-08-12 | 上海天慈国际药业有限公司 | Preparation method of dexmedetomidine and hydrochloride thereof |
CN110878039A (en) * | 2019-12-18 | 2020-03-13 | 株洲千金药业股份有限公司 | Preparation method of Sacubitril valsartan sodium impurity |
CN115611857B (en) * | 2022-09-09 | 2024-05-31 | 上海伍夫科技有限公司 | Preparation method of 2-methyl-5- (1-methylpyrrolidine-2-yl) pyridine |
CN115772088A (en) * | 2022-12-28 | 2023-03-10 | 海门瑞一医药科技有限公司 | Preparation method of tert-butoxy (bisdimethylamino) methane |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0055175B1 (en) | 1980-12-23 | 1984-06-13 | Air Industrie | Thermo-electrical plants |
US5250552A (en) | 1991-05-09 | 1993-10-05 | Warner-Lambert Company | 3-[thiazolidinone, oxazolidinone, imidazolidinone]-indoles as antiinflammatory agents |
US5250522A (en) | 1992-10-09 | 1993-10-05 | Ciba-Geigy Corporation | Phosphono/biaryl substituted amino acid derivatives |
FR2688503B1 (en) | 1992-03-16 | 1994-05-06 | Synthelabo | PROCESS FOR THE PREPARATION OF 2- (TETRAZOL-5-YL) - [1,1'-BIPHENYL] DERIVATIVES. |
EP0550313A1 (en) | 1991-12-30 | 1993-07-07 | Synthelabo | 2-(Tetranol-5-yl)-(1,1'-biphenyl)derivatives, their preparation and use as intermediates |
US5217996A (en) * | 1992-01-22 | 1993-06-08 | Ciba-Geigy Corporation | Biaryl substituted 4-amino-butyric acid amides |
US5412102A (en) | 1994-05-27 | 1995-05-02 | Syntex (U.S.A.) Inc. | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid |
TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GB0402262D0 (en) | 2004-02-02 | 2004-03-10 | Novartis Ag | Process for the manufacture of organic compounds |
AR057882A1 (en) * | 2005-11-09 | 2007-12-26 | Novartis Ag | DOUBLE ACTION COMPOUNDS OF ANGIOTENSIN RECEPTOR BLOCKERS AND NEUTRAL ENDOPEPTIDASE INHIBITORS |
EP1903027A1 (en) * | 2006-09-13 | 2008-03-26 | Novartis AG | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors |
BRPI0806700A8 (en) * | 2007-01-12 | 2019-01-22 | Novartis Ag | process |
EP2532673A3 (en) | 2007-05-10 | 2014-01-08 | R & D Biopharmaceuticals Gmbh | Tubulysine derivatives |
AR070176A1 (en) * | 2008-01-17 | 2010-03-17 | Novartis Ag | SYNTHESIS PROCESSES OF NEP INHIBITORS, INTERMEDIATE COMPOUNDS AND USE OF THE SAME IN SYNTHESIS |
MX2012008483A (en) * | 2010-01-22 | 2012-08-15 | Novartis Ag | Intermediates of neutral endopeptidase inhibitors and preparation method thereof. |
ES2608780T3 (en) * | 2010-08-23 | 2017-04-17 | Novartis Ag | New process for the preparation of intermediaries useful for the preparation of NEP inhibitors |
AU2011295170B2 (en) * | 2010-08-23 | 2014-12-18 | Novartis Ag | Process for the preparation of intermediates for the manufacture of NEP inhibitors |
-
2009
- 2009-01-15 AR ARP090100121A patent/AR070176A1/en unknown
- 2009-01-15 PE PE2009000047A patent/PE20091364A1/en not_active Application Discontinuation
- 2009-01-16 BR BRPI0906764-7A patent/BRPI0906764A2/en not_active IP Right Cessation
- 2009-01-16 NZ NZ600119A patent/NZ600119A/en not_active IP Right Cessation
- 2009-01-16 AU AU2009204759A patent/AU2009204759B2/en not_active Ceased
- 2009-01-16 US US12/863,213 patent/US8580974B2/en active Active
- 2009-01-16 CL CL2009000089A patent/CL2009000089A1/en unknown
- 2009-01-16 RU RU2010133903/04A patent/RU2513521C2/en not_active IP Right Cessation
- 2009-01-16 WO PCT/EP2009/050510 patent/WO2009090251A2/en active Application Filing
- 2009-01-16 PL PL09702021T patent/PL2245009T3/en unknown
- 2009-01-16 HU HUE09702021A patent/HUE030606T2/en unknown
- 2009-01-16 TW TW098101721A patent/TWI422370B/en not_active IP Right Cessation
- 2009-01-16 CA CA2711529A patent/CA2711529C/en not_active Expired - Fee Related
- 2009-01-16 PT PT97020218T patent/PT2245009T/en unknown
- 2009-01-16 MY MYPI2010003112A patent/MY169425A/en unknown
- 2009-01-16 SG SG2013004098A patent/SG187491A1/en unknown
- 2009-01-16 KR KR1020107018152A patent/KR101587668B1/en not_active IP Right Cessation
- 2009-01-16 ES ES09702021.8T patent/ES2602564T3/en active Active
- 2009-01-16 MX MX2010007842A patent/MX2010007842A/en active IP Right Grant
- 2009-01-16 EP EP09702021.8A patent/EP2245009B1/en active Active
- 2009-01-16 CN CN2009801061724A patent/CN101952249B/en active Active
- 2009-01-16 JP JP2010544498A patent/JP5739667B2/en active Active
- 2009-01-16 SI SI200931552A patent/SI2245009T1/en unknown
- 2009-01-16 NZ NZ586657A patent/NZ586657A/en not_active IP Right Cessation
- 2009-01-16 CN CN201310143383.3A patent/CN103483236B/en active Active
-
2010
- 2010-06-28 IL IL206664A patent/IL206664A0/en unknown
- 2010-06-30 TN TN2010000304A patent/TN2010000304A1/en unknown
- 2010-06-30 MA MA32970A patent/MA31951B1/en unknown
- 2010-07-16 GT GT201000211A patent/GT201000211A/en unknown
- 2010-08-12 CO CO10099278A patent/CO6290677A2/en active IP Right Grant
- 2010-08-17 EC EC2010010405A patent/ECSP10010405A/en unknown
-
2013
- 2013-10-31 RU RU2013148670A patent/RU2636936C2/en not_active IP Right Cessation
- 2013-11-06 JP JP2013230570A patent/JP5800882B2/en active Active
- 2013-11-11 US US14/076,302 patent/US9061973B2/en active Active
-
2015
- 2015-05-18 US US14/715,129 patent/US9227934B2/en active Active
- 2015-11-12 US US14/939,513 patent/US9403766B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2009000089A1 (en) | Processes for preparing a derivative of y-amino-o-biphenyl-x-methyl-pentanoic acid, intermediate compounds and their preparation process; use of the compounds in the synthesis of nep inhibitor compounds, useful in cardiovascular diseases, such as hypertension, congestive heart failure, among others. | |
CO6400217A2 (en) | (1-PHENYL-2-PIRIDIN-4-IL) ETHYL ESTERS OF BENZOIC ACID AS PHOSPHODIESTERASE INHIBITORS | |
UY32142A (en) | PREPARATION OF A QUINOLINILOXIDIFENILCICLOPROPANODICARBOXAMIDA | |
EA201270550A1 (en) | PROCESS FOR OBTAINING COMPOUNDS FOR APPLICATION AS SGLT2 INHIBITORS | |
UY31367A1 (en) | DERIVATIVES OF NICOTINAMIDE, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS | |
MA31574B1 (en) | PYRAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF RAF | |
CR20110013A (en) | Heteroaryl Derivatives as DGAT1 Inhibitors | |
CO6290658A2 (en) | DERIVATIVES OF AZETIDINE AND CYCLLOBUTANE AS JACK INHIBITORS | |
AR074845A1 (en) | SYNTHESIS PROCEDURE OF IVABRADINE AND ITS ADDITION SALTS TO A PHARMACEUTICALLY ACCEPTABLE ACID | |
IN2014MN01521A (en) | ||
MA31080B1 (en) | CYCLED DERIVATIVES AS EG-5 INHIBITORS. | |
CY1115623T1 (en) | METHOD FOR COMPOSITION OF 7,8-DIMETHOXY-1,3-DIDHYRO-2H-3-BENZAZEPIN-2-ONE AND ITS APPLICATION TO THE SYNTHESIS OF IBABRADYN AS | |
AU2009310099A8 (en) | Agricultural compositions | |
NI201000049A (en) | METHOD TO PRODUCE 2'-DEOXY-5-AZACITIDINE (DECITABIN) | |
ES2721662T3 (en) | Process for the preparation of travoprost | |
PT2462098E (en) | Process for the preparation of derivatives of 1-(2-halobiphenyl-4-yl)-cyclopropanecarboxylic acid | |
UY33179A (en) | CARBOXYL ACID DERIVATIVES THAT INCLUDE A 2,5-REPLACED OXAZOLOPIRIMIDINE RING. | |
MX2010009926A (en) | New process for the preparatiion of cyclohexanecarboxylic acid dericatives. | |
BR112013015532B1 (en) | 2- (alkoxy or aryloxycarbonyl) -4-methyl-6- (2,6,6-trimethylcycloex-1-enyl) -hex-2-enoic acid, method for its preparation and uses | |
EA201592167A1 (en) | METHOD FOR OBTAINING DERIVATIVES OF PYRROLIDIN-2-CARBONIC ACID | |
UA113223C2 (en) | ARYLETINYLPYRIMIDINE | |
UY33507A (en) | PROCESS FOR THE PREPARATION OF ENOLATE SALTS OF 4-FLUORO-2-HYDROXIMETHYLENE-3-OXO-BUTIRATES | |
JO2851B1 (en) | Substituted 3-Benzofuranyl-Indol-2-One-3-Acetamidopiperazine Derivatives, Preparation Thereof And Therapeutic Application Thereof | |
WO2012052939A3 (en) | Preparation of bicyclo[2.2.2]octan-2-one compounds | |
MX2013004425A (en) | Diastereoselective preparation of bicyclo[2.2.2]octan-2-one compounds. |